Drug intelligence / Profile preview

RHB-104 + interferon beta-1a

Development stage: Unknown
Lead developer: RedHill Biopharma
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Oral, Intramuscular, Subcutaneous

Overview

RHB-104 + interferon beta-1a is a combination therapy consisting of an oral antibiotic combination (RHB-104) and interferon beta-1a. RHB-104 contains three antibiotics (clarithromycin, clofazimine, and rifabutin) with potent intracellular, antimycobacterial and anti-inflammatory properties. This combination was studied as an add-on therapy for relapsing-remitting multiple sclerosis, based on the hypothesis that Mycobacterium avium subspecies paratuberculosis (MAP) infection may contribute to autoimmune diseases.

Targets

IFNAR (Immune system modulation via type I interferon receptor)

Beyond the preview

Go deeper on RHB-104 + interferon beta-1a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RHB-104 + interferon beta-1a.

Explore the full profile